FORM 4

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average b	ourden								
-1	hours nor roomanas.	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Durgam Suresh K.						2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ITCI]								Check	all app Direc	o of Reporting Pe dicable) tor er (give title		son(s) to Is 10% Ov Other (s	vner		
(Last) (First) (Middle) C/O INTRA-CELLULAR THERAPIES, INC.						3. Date of Earliest Transaction (Month/Day/Year) 02/01/2024								X	below		1edica	below)	·		
430 EAST 29TH STREET					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) NEW YORK NY 10016																X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication															
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
		Table	I - No	on-Deriva	tive S	Secu	rities	Acc	quired	l, Dis	sposed of	, or B	enefic	ially	Own	ed					
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/				Execution Date,				3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4						Securi Benefi Owned	cially I Following	Form:	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price			orted saction(s) tr. 3 and 4)			(Instr. 4)			
Common Stock 02/01/2					024				A ⁽¹⁾		11,860	A	\$() 13		11,860		D			
Common	Stock			02/02/20	024				S ⁽²⁾		2,320	D	\$66.6	59(3)		9,540		D			
Common Stock 02/02/20				.024				S ⁽²⁾		3,847	D	\$67.4	19 ⁽⁴⁾	9(4) 5,693		D					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	ive Conversion Date (Month/Day/Year) y or Exercise Price of Derivative Security Conversion Date (Month/Day/Year)			saction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date		7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4) Amoun or Numbe of Title Shares		t r		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		0. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)						

Explanation of Responses:

- 1. Represents shares issued upon the vesting of performance stock units.
- 2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$66.1734 to \$67.1, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$67.15 to \$68.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

/s/ Lawrence J. Hineline, 02/05/2024 Attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.